β-Cell secretory capacity measured as the AIRpot in the Edmonton protocol subjects (A) and in the CIT07 protocol subjects (B) over time after transplantation. The Edmonton cohort underwent islet transplantation between 2002 and 2003, and the CIT07
cohort underwent islet transplantation between 2008 and 2012. The hashed area gives the 95% CI for the β-cell secretory capacity
in the normal control group. Of the Edmonton protocol subjects, one returned to insulin soon after initial study and lost
all islet graft function by 365 days (□), one returned to insulin at 9 months and received a second islet infusion (○), two
returned to insulin at 11 months and exhibited declines in β-cell secretory capacity at 365 days (△, ◇), and one initially
studied at 365 days remained insulin independent at 730 days with stable β-cell secretory capacity (⌂). All nine of the CIT07
protocol subjects to have reached 365 days remained insulin independent.